Top

Journal of Diabetes & Metabolic Disorders

Published in:

Open Access 01-12-2014 | Research article

A comparative study of broccoli sprouts powder and standard triple therapy on cardiovascular risk factors following H.pylori eradication: a randomized clinical trial in patients with type 2 diabetes

Authors: Parvin Mirmiran, Zahra Bahadoran, Mahdieh Golzarand, Homayoun Zojaji, Fereidoun Azizi

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2014

Abstract

Background

In this clinical trial we compared the effects of broccoli sprouts powder, as an alternative and complementary treatment, to those of standard triple therapy, as a common medical treatment, on cardiovascular risk factors following the H.pylori eradication in patients with type 2 diabetes.

Methods

Eighty-six type 2 diabetic patients with positive H.pylori stool antigen test (HpSAg) were randomized to receive one of the three following regimens: STT) Standard triple therapy (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice a day for 14 days), BSP) 6 g/d broccoli sprouts powder for 28 days, and combination of these as STT + BSP. After 4 weeks of treatment, H.pylori eradication rates were assessed by HpSAg. Anthropometric measures, blood pressure, serum lipids and lipoproteins as well as serum high sensitive- C reactive protein were also assessed at baseline and at the second examination.

Results

Seventy-seven participants completed the study [STT (n = 28), BSP (n = 25), STT + BSP (n = 24)]. The H.pylori eradication rates were 89.3%, 56.0% and 91.7% in STT, BSP and STT + BSP groups, respectively. After the treatment, both systolic and diastolic blood pressure significantly decreased in STT + BSP group (P < 0.05). Serum triglycerides and TG/HDL-C ratio increased in STT patients group (<0.05). Serum hs-CRP levels significantly decreased in the patients who were treated with BSP per se (3.0 ± 2.5 at baseline vs. 2.3 ± 2.1 after the treatment, P < 0.05).

Conclusion

Compared to standard triple therapy, BSP regimen in addition to considerable effects on H.pylori eradication had also favorable properties on cardiovascular risk factors following the H.pylori eradication.

Available only for authorised users

Zhou X, Zhang C, Wu J, Zhang G: Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract 2013, 99: 200–208. 10.1016/j.diabres.2012.11.012PubMedCrossRef

Devrajani BR, Shah SZ, Soomro AA, Devrajani T: Type 2 diabetes mellitus: a risk factor for Helicobacter pylori infection: a hospital based case–control study. Int J Diabetes Dev Ctries 2010, 30: 22–26. 10.4103/0973-3930.60008PubMedPubMedCentralCrossRef

Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A: Helicobacter pylori infection and diabetes. Minerva Med 2010, 101: 115–119.PubMed

Rossi C, Quadri R, Cavallo Perin P: Helicobacter pylori infection and diabetic complications. Diabetes Nutr Metab 2004, 17: 65–68.PubMed

de Luis DA, Lahera M, Cantón R, Boixeda D, San Román AL, Aller R, de La Calle H: Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. Diabetes Care 1998, 21: 1129–1132. 10.2337/diacare.21.7.1129PubMedCrossRef

Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U: Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009, 102: 1116–1120. 10.1097/SMJ.0b013e3181bca538PubMedCrossRef

Keenan JI, Salm N, Hampton MB, Wallace AJ: Individual and combined effects of foods on Helicobacter pylori growth. Phytother Res 2010, 24: 1229–1233.PubMedCrossRef

Keenan JI, Salm N, Wallace AJ, Hampton MB: Using food to reduce H. pylori-associated inflammation. Phytother Res 2012, 26: 1620–1625. 10.1002/ptr.4618PubMedCrossRef

Lee SY, Shin YW, Hahm KB: Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J Dig Dis 2008, 9: 129–139. 10.1111/j.1751-2980.2008.00334.xPubMedCrossRef

10.

Haristoy X, Angioi-Duprez K, Duprez A, Lozniewski A: Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrob Agents Chemother 2003, 47: 3982–3984. 10.1128/AAC.47.12.3982-3984.2003PubMedPubMedCentralCrossRef

11.

Yanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, Zhang S, Tauchi M, Suzuki H, Hyodo I, Yamamoto M: Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res (Phila) 2009, 2: 353–360. 10.1158/1940-6207.CAPR-08-0192PubMedCrossRef

12.

Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002, 99: 7610–7615. 10.1073/pnas.112203099PubMedPubMedCentralCrossRef

13.

Lip GH, Wise R, Beevers G: Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H pylori infection and hypertension. BMJ 1996, 312: 250–251.PubMedPubMedCentralCrossRef

14.

Harvey R, Lane A, Murray L, Harvey I, Nair P, Donovan J: Effect of Helicobacter pylori infection on blood pressure: a community based cross sectional study. BMJ 2001, 323: 264–265.PubMedPubMedCentralCrossRef

15.

Migneco A, Ojetti V, Specchia L, Franceschi F, Candelli M, Mettimano M, Montebelli R, Savi L, Gasbarrini G: Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter 2003, 8: 585–589. 10.1111/j.1523-5378.2003.00180.xPubMedCrossRef

16.

Wu L, Noyan Ashraf MH, Facci M, Wang R, Paterson PG, Ferrie A, Juurlink BH: Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci U S A 2004, 101: 7094–7099. 10.1073/pnas.0402004101PubMedPubMedCentralCrossRef

17.

Christiansen B, Bellostas Muguerza N, Petersen AM, Kveiborg B, Madsen CR, Thomas H, Ihlemann N, Sørensen JC, Køber L, Sørensen H, Torp-Pedersen C, Domínguez H: Ingestion of broccoli sprouts does not improve endothelial function in humans with hypertension. PLoS One 2010, 5: e12461. 10.1371/journal.pone.0012461PubMedPubMedCentralCrossRef

18.

Nicolucci A, De Berardis G, Sacco M, Tognoni G: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007, 30: 162–172. 10.2337/dc07-9917CrossRef

19.

Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D: Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004, 53: 701–710. 10.2337/diabetes.53.3.701PubMedCrossRef

20.

Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002, 106: 1211–1218. 10.1161/01.CIR.0000027569.76671.A8PubMedCrossRef

21.

Lee SH, Lee BW, Won HK, Moon JH, Kim KJ, Kang ES, Cha BS, Lee HC: Postprandial Triglyceride is associated with fasting Triglyceride and HOMA-IR in Korean subjects with type 2 diabetes. Diabetes Metab J 2011, 35: 404–410. 10.4093/dmj.2011.35.4.404PubMedPubMedCentralCrossRef

22.

Dobiasova M, Frohlich J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo-B-lipoprotein-depleted plasma. Clin Biochem 2001, 34: 583–588. 10.1016/S0009-9120(01)00263-6PubMedCrossRef

23.

Frohilich J, Dobiasova M: Fractional esterification rate of cholesterol and ratio of triglyceride to HDL-C are powerful predictors of positive finding on coronary angiography. Clin Chem 2003, 49: 1873–1880. 10.1373/clinchem.2003.022558CrossRef

24.

Kahlon TS, Chapman MH, Smith GE: In vitro binding of bile acids by spinach, kale, brusseles sprouts, broccoli, mustard green, green bell pepper, cabbage and collards. Food Chem 2007, 100: 1531–1536. 10.1016/j.foodchem.2005.12.020CrossRef

25.

Dunn SE, LeBlanc GA: Hypocholesterolemic properties of plant indoles. Inhibition of acyl-CoA:cholesterol acyltransferase activity and reduction of serum LDL/VLDL cholesterol levels by glucobrassicin derivatives. Biochem Pharmacol 1994, 47: 359–364.PubMedCrossRef

26.

LeBlanc GA, Stuart JD, Dunn SE, Baldwin WS: Effect of the plant compound indole-3-carbinol on hepatic cholesterol homoeostasis. Food Chem Toxicol 1994, 32: 633–639. 10.1016/0278-6915(94)90007-8PubMedCrossRef

27.

Maiyoh GK, Kuh JE, Casaschi A, Theriault AG: Cruciferous indole-3-carbinol inhibits apolipoprotein B secretion in HepG2 cells. J Nutr 2007, 137: 2185–2189.PubMedCrossRef

28.

Murashima M, Watanabe S, Zhuo XG, Uehara M, Kurashige A: Phase 1 study of multiple biomarkers for metabolism and oxidative stress after one-week intake of broccoli sprouts. Biofactors 2004, 22: 271–275. 10.1002/biof.5520220154PubMedCrossRef

29.

Bahadoran Z, Mirmiran P, Hosseinpanah F, Rajab A, Asghari G, Azizi F: Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Diabetes Res Clin Pract 2012, 96: 348–354. 10.1016/j.diabres.2012.01.009PubMedCrossRef

30.

Jafarzadeh A, Hassanshahi GH, Nemati M: Serum levels of high-sensitivity C-reactive protein (hs-CRP)in Helicobacter pylori-infected peptic ulcer patients and its association with bacterial CagA virulence factor. Dig Dis Sci 2009, 54: 2612–2616. 10.1007/s10620-008-0686-zPubMedCrossRef

31.

Ishida Y, Suzuki K, Taki K, Niwa T, Kurotsuchi S, Ando H, Iwase A, Nishio K, Wakai K, Ito Y, Hamajima N: Significant association between Helicobacter pylori infection and serum C-reactive protein. Int J Med Sci 2008, 5: 224–229.PubMedPubMedCentralCrossRef

32.

Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52: 812–817. 10.2337/diabetes.52.3.812PubMedCrossRef

33.

Ridker PM, Hennekens CH, Buring JE: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836–843. 10.1056/NEJM200003233421202PubMedCrossRef

34.

Russell PT, Rozenn NL, Bruce MP: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997, 17: 1121–1127. 10.1161/01.ATV.17.6.1121CrossRef

35.

Gen R, Demir M, Ataseven H: Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010, 103: 190–196. 10.1097/SMJ.0b013e3181cf373fPubMedCrossRef

36.

Kanbay M, Gür G, Yücel M, Yilmaz U, Boyacioğlu S: Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 2005, 50: 1228–1231. 10.1007/s10620-005-2764-9PubMedCrossRef

37.

Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Kim BI, Keum DK: Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc 2005, 97: 508–513.PubMedPubMedCentral

38.

Pellicano R, Oliaro E, Fagoonee S, Astegiano M, Berrutti M, Saracco G, Smedile A, Repici A, Leone N, Castelli A, Luigiano C, Fadda M, Rizzetto M: Clinical and biochemical parameters related to cardiovascular disease after Helicobacter pylori eradication. Int Angiol 2009, 28: 469–473.PubMed

39.

Ritz SA, Wan J, Diaz-Sanchez D: Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. Am J Physiol Lung Cell Mol Physiol 2009, 292: L33-L39.CrossRef

40.

Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, Kong AN: Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling. Chem Biol Interact 2009, 179: 202–211. 10.1016/j.cbi.2008.12.014PubMedCrossRef

41.

Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhäuser C: Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001, 276: 32008–32015. 10.1074/jbc.M104794200PubMedCrossRef

Title: A comparative study of broccoli sprouts powder and standard triple therapy on cardiovascular risk factors following H.pylori eradication: a randomized clinical trial in patients with type 2 diabetes
Authors: Parvin Mirmiran
Zahra Bahadoran
Mahdieh Golzarand
Homayoun Zojaji
Fereidoun Azizi
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2014
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1186/2251-6581-13-64

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Determinants of diabetes knowledge in a cohort of Nigerian diabetics

Effect of garlic on lipid profile and expression of LXR alpha in intestine and liver of hypercholesterolemic mice

Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial

Effect of spent turmeric on kidney glycoconjugates in streptozotocin-induced diabetic rats

Predictive factors of diabetic complications: a possible link between family history of diabetes and diabetic retinopathy

Tertiary structure prediction and identification of druggable pocket in the cancer biomarker – Osteopontin-c

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials